Human papillomavirus vaccine (GlaxoSmithKline)

N/A

Report date: 2022/08/16 20:00:19

Base Information

Drug NameHuman papillomavirus vaccine (GlaxoSmithKline)

Drug Alias NamePD-E7/AS02B vaccine人乳头瘤病毒HPV-16 E7/AS02B vaccineHuman papillomavirus type 16 E7 protein-based vaccine - GlaxoSmithKline

ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCervical Intraepithelial NeoplasiaPapillomavirus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBulgariaUnited States +[8]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc

Inactive CompaniesN/A

Active IndicationsCervical Intraepithelial Neoplasia

Inactive IndicationsPapillomavirus Infections

Other Information

ATC CodeN/A